Matches in Wikidata for { <http://www.wikidata.org/entity/Q98196181> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q98196181 description "article scientifique publié en 2020" @default.
- Q98196181 description "artículu científicu espublizáu en xunetu de 2020" @default.
- Q98196181 description "im Juli 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q98196181 description "scientific article published on 31 July 2020" @default.
- Q98196181 description "wetenschappelijk artikel" @default.
- Q98196181 description "наукова стаття, опублікована 31 липня 2020" @default.
- Q98196181 name "Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study" @default.
- Q98196181 name "Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study" @default.
- Q98196181 type Item @default.
- Q98196181 label "Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study" @default.
- Q98196181 label "Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study" @default.
- Q98196181 prefLabel "Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study" @default.
- Q98196181 prefLabel "Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study" @default.
- Q98196181 P1433 Q98196181-38BEA0AC-FAE8-4183-837A-1D2519979DCB @default.
- Q98196181 P1476 Q98196181-0762BB2B-3F20-4649-9A33-24FEF019630D @default.
- Q98196181 P2093 Q98196181-2167DB91-0A53-4674-A763-DE6E1EFBB0DA @default.
- Q98196181 P2093 Q98196181-4BEA2E5B-775F-46F9-8FB9-44837CC64961 @default.
- Q98196181 P2093 Q98196181-4E4776F0-C125-4721-BA94-DD7C8B9284DD @default.
- Q98196181 P2093 Q98196181-56FFC6D2-ADFA-4C4E-A463-B074E932F795 @default.
- Q98196181 P2093 Q98196181-5A8FF026-DCB3-4CD2-ACDC-93DBD0D66E5C @default.
- Q98196181 P2093 Q98196181-68AE9BBC-C9D1-46F6-A35B-932570B51DDA @default.
- Q98196181 P2093 Q98196181-70641D41-2017-40AC-83AE-EADA75955164 @default.
- Q98196181 P2093 Q98196181-C5244446-AA51-4FCE-ADEF-A56A0BC42CC4 @default.
- Q98196181 P2093 Q98196181-D0ECC003-1B00-496C-8180-717A64F33C8B @default.
- Q98196181 P2093 Q98196181-D3480534-0AA8-42FA-802F-1667F85CBB17 @default.
- Q98196181 P2093 Q98196181-E3A9845C-CD85-4A05-9D15-77B42A9A90DE @default.
- Q98196181 P2093 Q98196181-E88416C2-E001-4271-B933-E4077EC613F9 @default.
- Q98196181 P2093 Q98196181-F449EC63-7C8F-4D99-B359-7E248B7DBBB2 @default.
- Q98196181 P2093 Q98196181-F7504989-17F3-4C12-BDB6-34C2DFA3042B @default.
- Q98196181 P2093 Q98196181-F8356057-BDAA-4C05-B7C2-46F3428B0A07 @default.
- Q98196181 P31 Q98196181-7148EA1C-CE77-4A49-B6E2-E63640912A94 @default.
- Q98196181 P356 Q98196181-88390070-A487-4A05-869C-3CD702C1015B @default.
- Q98196181 P577 Q98196181-C9D4C64C-5136-4E66-BEA6-45E0AE7A5BBF @default.
- Q98196181 P698 Q98196181-BC66E5C7-3F30-4FBF-8661-6EE8D0A70909 @default.
- Q98196181 P921 Q98196181-355CAF5F-1074-46BB-A218-43CF6ABD08F0 @default.
- Q98196181 P921 Q98196181-E5623301-8B0D-4A52-AED7-C0C32886A565 @default.
- Q98196181 P356 J.DLD.2020.06.034 @default.
- Q98196181 P698 32747302 @default.
- Q98196181 P1433 Q15766194 @default.
- Q98196181 P1476 "Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study" @default.
- Q98196181 P2093 "Aparicio Thomas" @default.
- Q98196181 P2093 "Barbier Emilie" @default.
- Q98196181 P2093 "Dahan Laeticia" @default.
- Q98196181 P2093 "Hautefeuille Vincent" @default.
- Q98196181 P2093 "Laurent-Puig Pierre" @default.
- Q98196181 P2093 "Legoux Jean-Louis" @default.
- Q98196181 P2093 "Lepage Côme" @default.
- Q98196181 P2093 "Lièvre Astrid" @default.
- Q98196181 P2093 "Malka David" @default.
- Q98196181 P2093 "Manfredi Sylvain" @default.
- Q98196181 P2093 "Michel Pierre" @default.
- Q98196181 P2093 "Phelip Jean-Marc" @default.
- Q98196181 P2093 "Tougeron David" @default.
- Q98196181 P2093 "Turpin Anthony" @default.
- Q98196181 P2093 "Zaanan Aziz" @default.
- Q98196181 P31 Q13442814 @default.
- Q98196181 P356 "10.1016/J.DLD.2020.06.034" @default.
- Q98196181 P577 "2020-07-31T00:00:00Z" @default.
- Q98196181 P698 "32747302" @default.
- Q98196181 P921 Q108566365 @default.
- Q98196181 P921 Q413299 @default.